Ligand Pharma (LGND) Announces EC Approval of Revolade as SAA Treatment
Tweet Send to a Friend
Ligand Pharma (NASDAQ: LGND) announces the European Commission has approved Revolade® (eltrombopag), a Novartis product, for the treatment of adults ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE